<DOC>
	<DOCNO>NCT01135446</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamics ( PD ) , pharmacokinetics ( PK ) , safety tolerability follow single oral dos 0.001 mg 2.5 mg dapagliflozin healthy subject .</brief_summary>
	<brief_title>Pharmacodynamics , Pharmacokinetics , Safety Tolerability Ultra Low Doses Dapagliflozin Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy men woman WOCBP use acceptable method contraception Women nurse History GI disease Any GI surgery could impact study drug absorption Glucosuria screen Day 2 Abnormal liver function test ( ALT , AST total bilirubin &gt; 10 % ULN ) History current recurrent UTI History Diabetes Mellitus History chronic recurrent vulvovaginal mycotic infection Estimated creatinine clearance ( ClCr ) &lt; 80 mL/min use CockroftGault formula History allergy SGLT2 inhibitor relate compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>